Open an account

Kamada

KMDA · NASDAQ

$7.85+$0.24 (+3.15%)TodayMarket closed ·
Prev close $7.61

About KMDA

Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. The company is headquartered in Rehovot, Central(Hamerkaz) and currently employs 393 full-time employees. The company went IPO on 2005-08-01. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.

Employees
462
Headquarters
Rehovot, Central(HaMerkaz)
Listed
Aug 1, 2005
Sector
Health Care
Industry
Biotechnology
Website
kamada.com

KMDA key statistics

Market cap
452.90M
Price-earnings ratio
20.03
Dividend yield
3.29%
Average volume
84.95K
Volume
110.63K
Open price
$7.69
High today
$7.91
Low today
$7.69
52 Week high
$9.35
52 Week low
$6.55

Kamada (KMDA) at a glance

Kamada (KMDA) last traded at $7.85, with a market cap of 452.90M, a price-to-earnings ratio of 20.03 and a dividend yield of 3.29%.

Today the stock has traded between $7.69 and $7.91. The current price is 2.1% above the day's low and 0.7% below its high.

Volume so far is 110.63K shares, above the average of 84.95K shares a day.

Over the past year Kamada has ranged from $6.55 to $9.35, and now sits 46% of the way up that range.

Kamada met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $0.16 per share against an estimate of $0.1148.

The average analyst price target is $13.77, 75.4% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $13.77
Low
$11.11
Now
$7.85
High
$15.75

KMDA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 23.6% on average.

  1. Q3 FY24: reported $0.07 per share against an estimate of $0.068
  2. Q4 FY24: reported $0.07 per share against an estimate of $0.0544
  3. Q1 FY25: reported $0.07 per share against an estimate of $0.0689
  4. Q2 FY25: reported $0.13 per share against an estimate of $0.0893
  5. Q3 FY25: reported $0.09 per share against an estimate of $0.0944
  6. Q4 FY25: reported $0.06 per share against an estimate of $0.0791
  7. Q1 FY26: reported $0.07 per share against an estimate of $0.1173
  8. Q2 FY26: reported $0.16 per share against an estimate of $0.1148

KMDA news

  • Kamada Q1 2026 Earnings Call: Complete Transcript

  • What's Next: Kamada's Earnings Preview

  • Vandana Singh

    Kamada Shuts Down Phase 3 Study For Genetic Condition, Reiterates Outlook

  • An Overview of Kamada's Earnings

  • An Overview of Kamada's Earnings

  • What's Next: Kamada's Earnings Preview

Similar companies

Companies in the same industry as Kamada

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.